Company: SNY
Filing Date: 2025-10-27
Form Type: 424B5
Source: 0001193125-25-250786
Chunk: 9

Company: Sanofi
Filing Date: 2025-10-27
Form: 424B5
Chunk 9
---
 holders thereof to receive two potential milestone payments of $2.00 and $4.00 per CVR on the attainment of
future development and regulatory milestones within the applicable milestone period, respectively, for BLU-808. The total equity value of the transaction, including potential CVR payments, represented
approximately $9.5 billion on a fully diluted basis.

On July 22, 2025, Sanofi announced that it had entered into an agreement
to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, United Kingdom. The acquisition brings to Sanofi an early-stage combination vaccine candidate for respiratory syncytial virus and human
metapneumovirus, both respiratory viruses, and is expected to expand Sanofi’s capabilities in vaccine design and development with Vicebio’s “Molecular Clamp” technology. Under the terms of the agreement, Sanofi would acquire
all of Vicebio’s share capital for a total upfront payment of $1.15 billion, with potential milestone payments of up to $450 million based on development and regulatory achievements. The transaction is expected to close in the fourth
quarter of 2025, subject to customary closing conditions, including receipt of regulatory approvals

On August 6, 2025, Sanofi
acquired all outstanding common shares of Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $8 per share in cash at
closing. Based on $8.00 per share, the total equity value of Vigil represented approximately $470 million (on a fully diluted basis). In addition, Vigil’s shareholders received one CVR per Vigil share entitling the holder to receive a
deferred cash payment of $2.00, contingent upon the first commercial sales of VG-3927.

S-6

On September 24, 2025, Sanofi Ventures announced an additional $625 million
multi-year capital commitment from Sanofi, increasing its total assets under management to over $1.4 billion. Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in biotech and artificial intelligence/digital health
companies.

Our registered office is located at 46, avenue de la Grande Armée, 75017 Paris, France, and we can be contacted at the
following email address: investor.relations@sanofi.com; or the following telephone number: +33 1 53 77